Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Conditions
Interventions
Apremilast
Placebo
+1 more
Locations
46
United States
Arizona Skin and Laser Therapy Inst., Ltd.
Phoenix, Arizona, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Clinical Science Institute
Santa Monica, California, United States
Florida Academic Dermatology Center
Miami, Florida, United States
Start Date
November 22, 2010
Primary Completion Date
March 15, 2012
Completion Date
November 30, 2016
Last Updated
March 15, 2022
NCT07474792
NCT06979453
NCT07116967
NCT07250802
NCT07449702
NCT07290569
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions